Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Nephrology

Long-term Prognosis and Kidney Transplantation

At a Glance

MPGN and C3G can progress to kidney failure, but individual risk depends on protein in the urine, kidney function, blood albumin, biopsy findings, and disease subtype. Transplantation is possible, although the disease can recur and requires close monitoring.

Living with a chronic kidney condition like IC-MPGN or C3G means thinking about the future. While the path for every person is different, understanding the long-term outlook helps you and your care team make the best decisions for your health [1][2].

Understanding the Long-Term Outlook

It is important to be honest about the numbers: both IC-MPGN and C3G can be progressive conditions. Research suggests that roughly 40% to 50% of people with these diagnoses may progress to kidney failure within 10 years [1][3].

However, this is an average from historical cohorts, not a guarantee. These figures group together many different subtypes, and outcomes vary substantially based on whether the disease is primary or from a treatable secondary cause. Your individual risk depends heavily on several “prognostic markers”—the data points that help doctors predict how your kidneys will behave [4]:

  • Proteinuria (Protein in Urine): Having more than 1 gram of protein in your urine per day at the one-year mark is one of the strongest signs that the disease is active and your risk of failure is higher [2][5].
  • eGFR (Kidney Function): Starting with a lower kidney function (eGFR) at the time of diagnosis is a risk factor for faster progression [4][6].
  • Serum Albumin: Low levels of this protein in your blood (hypoalbuminemia) can indicate more severe kidney damage [4].
  • Biopsy Findings: The presence of crescents (a specific shape of inflammation in the filters) or significant scarring (sclerosis) suggests a more aggressive or advanced disease course [7][8].

Transitioning to Kidney Replacement Therapy

If your kidneys can no longer keep up with your body’s needs, you will transition to Kidney Replacement Therapy [9]. Suitable patients may undergo preemptive transplantation before dialysis, or choose hemodialysis, peritoneal dialysis, or comprehensive conservative kidney management. Evaluation for a transplant should begin well before kidney failure occurs.

The Reality of Kidney Transplantation

A transplant is considered the best treatment for kidney failure, but for patients with MPGN or C3G, there is a unique challenge: recurrence. Because the underlying immune system issue that caused the disease is still in your body, the “pattern of injury” can return and attack the new kidney (the allograft) [10][11].

  • Recurrence Rates: Recurrence is common but varies significantly by disease subtype. Some studies show recurrence in up to 62% of patients with specific complement-mediated diseases [10]. In other series, recurrence was seen in nearly 90% of recipients when very early “protocol biopsies” (looking under a microscope before clinical symptoms appear) were performed [12].
  • Impact on the New Kidney: When the disease clinically recurs, it can cause the new kidney to fail over time. One study found that 58% of patients with a confirmed recurrence eventually lost their new kidney [8].

Emerging Hope for Transplant Patients

While recurrence is a serious concern, new treatments are providing more options than ever before.

  • Complement Inhibitors: Researchers are testing medications like pegcetacoplan specifically in the transplant setting. In the NOBLE trial, patients with recurrent disease saw a significant reduction in C3 deposits and a decrease in proteinuria (falling by an average of over 54% in some groups) [13].
  • Iptacopan: There is also emerging evidence that Factor B inhibitors can help reduce deposits and stabilize function in a new kidney [14][15].

Note: The use of complement inhibitors in the transplant setting is currently largely investigational or center-specific.

Your transplant team will likely monitor your new kidney very closely, especially in the first few months, using blood tests and sometimes “protocol biopsies” (planned biopsies even if labs are stable) to catch recurrence as early as possible [12][10]. Identifying it early means your team can adjust your medications to help protect your new kidney for as long as possible.

Common questions in this guide

What is the long-term outlook for MPGN or C3G?
Historical studies suggest that about 40% to 50% of people with IC-MPGN or C3G progressed to kidney failure within 10 years. This is an average, not a prediction for one person; the outlook varies with the disease subtype, cause, kidney function, urine protein, blood albumin, and biopsy findings.
Which test results can signal a higher risk of kidney failure?
More than 1 gram of protein in the urine per day after the first year, a lower eGFR at diagnosis, low blood albumin, crescents, and significant scarring on biopsy are linked with faster progression. Your nephrologist will interpret these findings together rather than using one result alone.
When should I begin evaluation for a kidney transplant?
Transplant evaluation should start well before kidney failure occurs. Some suitable patients may receive a preemptive transplant before dialysis, while others may choose hemodialysis, peritoneal dialysis, or conservative kidney management.
Can MPGN or C3G return after a kidney transplant?
Yes. The immune or complement problem that caused the original kidney injury can affect the transplanted kidney, and recurrence risk varies widely by subtype. Studies have reported recurrence in up to 62% for some complement-mediated diseases, while protocol biopsies in one series detected earlier recurrence in nearly 90%.
How is a transplanted kidney monitored for recurrent disease?
The transplant team may use regular blood tests and urine protein measurements, especially during the first few months. Planned protocol biopsies may detect recurrence before symptoms or routine laboratory changes appear, allowing the team to adjust treatment.
Can complement inhibitors treat recurrence after transplantation?
Medications such as pegcetacoplan and iptacopan are being studied for recurrent complement-mediated disease and may reduce deposits or proteinuria in some patients. Their use after transplant remains investigational or center-specific, so the transplant team must decide whether they are appropriate.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on membranoproliferative glomerulonephritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are my specific risk factors—such as my current proteinuria levels or biopsy results—that might predict how fast my disease progresses?
  2. 2.If my kidneys fail, how do we decide when is the right time to start the transplant evaluation process?
  3. 3.What is the typical recurrence rate for my specific subtype (IC-MPGN or C3G) after transplantation at this center?
  4. 4.If the disease recurs in a new kidney, are we able to use newer complement inhibitors like pegcetacoplan or iptacopan to protect the graft?
  5. 5.How often will we monitor my new kidney for signs of recurrence using protein tests or 'protocol' biopsies?

References

References (15)
  1. 1

    Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry.

    Masoud S, Wong K, Pitcher D, et al.

    Kidney international 2025; (108(3)):455-469 doi:10.1016/j.kint.2025.06.003.

    PMID: 40582408
  2. 2

    Natural History and Clinical Associations with Long-Term Outcomes in Primary C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative GN.

    Nanchen G, Marasà M, Breno M, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2026; (21(4)):626-640 doi:10.2215/CJN.0000000953.

    PMID: 41433110
  3. 3

    Clinical Presentation, Treatment Patterns, Burden of Disease, and the Association of Proteinuria with Clinical Outcomes in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic Review.

    Caravaca-Fontán F, Fakhouri F, Pickering MC, et al.

    Nephron 2026; (150(1)):25-40 doi:10.1159/000548245.

    PMID: 40971335
  4. 4

    Predictors of poor kidney outcome in children with C3 glomerulopathy.

    Pınarbaşı AS, Dursun I, Gokce I, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(5)):1195-1205 doi:10.1007/s00467-020-04799-7.

    PMID: 33130981
  5. 5

    Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.

    Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al.

    Kidney international reports 2025; (10(4)):1223-1236 doi:10.1016/j.ekir.2025.01.024.

    PMID: 40303231
  6. 6

    Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.

    Nakagawa N, Mizuno M, Kato S, et al.

    PloS one 2021; (16(9)):e0257397 doi:10.1371/journal.pone.0257397.

    PMID: 34520493
  7. 7

    C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.

    Wong EKS, Marchbank KJ, Lomax-Browne H, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2021; (16(11)):1639-1651 doi:10.2215/CJN.00320121.

    PMID: 34551983
  8. 8

    Natural History and Progression of Recurrent C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative GN in Kidney Transplantation.

    Ruiz-Cabello JE, Yandian F, Torres IB, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2026; (21(9)):1593-1605 doi:10.2215/CJN.0000001117.

    PMID: 42462202
  9. 9

    [Diagnosis and treatment of glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury].

    Rudnicki M, Windpessl M, Eller K, et al.

    Wiener klinische Wochenschrift 2023; (135(Suppl 5)):688-695 doi:10.1007/s00508-023-02264-7.

    PMID: 37728653
  10. 10

    Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation.

    Caravaca-Fontán F, Polanco N, Villacorta B, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(1)):222-235 doi:10.1093/ndt/gfac148.

    PMID: 35404425
  11. 11

    Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

    Halfon M, Taffé P, Bucher C, et al.

    Kidney international reports 2025; (10(1)):75-86 doi:10.1016/j.ekir.2024.10.008.

    PMID: 39810762
  12. 12

    C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First 2 Years after Transplantation.

    Tarragón B, Peleg Y, Jagannathan G, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2024; (19(8)):1005-1015 doi:10.2215/CJN.0000000000000474.

    PMID: 39116277
  13. 13

    Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis.

    Bomback AS, Daina E, Remuzzi G, et al.

    Kidney international reports 2025; (10(1)):87-98 doi:10.1016/j.ekir.2024.09.030.

    PMID: 39810766
  14. 14

    Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

    Wong E, Nester C, Cavero T, et al.

    Kidney international reports 2023; (8(12)):2754-2764 doi:10.1016/j.ekir.2023.09.017.

    PMID: 38106570
  15. 15

    Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.

    Escudero-Saiz VJ, Gonzalez Á, García-Herrera A, et al.

    Kidney medicine 2024; (6(6)):100823 doi:10.1016/j.xkme.2024.100823.

    PMID: 38741947

This page explains long-term prognosis and kidney transplantation for MPGN and C3G for informational purposes only and does not replace medical advice. Your nephrologist and transplant team can interpret your individual risks and treatment options.